Video Upload Options

References

1. Brisken; Malley (December 2, 2010). "Hormone Action in the Mammary Gland". Cold Spring Harb. Perspect. Biol. (Cold Spring Harb Perspect Biol) 2 (12): a003178. doi:10.1101/cshperspect.a003178. PMID 20739412.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2982168
2. "Role of IGF-I in normal mammary development". Breast Cancer Res. Treat. 47 (3): 201–8. 1998. doi:10.1023/a:1005998832636. PMID 9516076.  https://dx.doi.org/10.1023%2Fa%3A1005998832636
3. "Early mammary development: growth hormone and IGF-1". J Mammary Gland Biol Neoplasia 2 (1): 49–57. 1997. PMID 10887519.  http://www.ncbi.nlm.nih.gov/pubmed/10887519
4. "Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development". Endocrinology 140 (11): 5075–81. 1999. doi:10.1210/endo.140.11.7095. PMID 10537134. http://press.endocrine.org/doi/10.1210/endo.140.11.7095?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed. 
5. "IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis". J Mammary Gland Biol Neoplasia 5 (1): 7–17. 2000. PMID 10791764.  http://www.ncbi.nlm.nih.gov/pubmed/10791764
6. Isaksson, Erika; Sahlin, Lena; Söderqvist, Gunnar; von Schoultz, Eva; Masironi, Britt; Wickman, Marie; Wilking, Nils; von Schoultz, Bo et al. (1999). "Expression of sex steroid receptors and IGF-1 mRNA in breast tissue — effects of hormonal treatment". J. Steroid Biochem. Mol. Biol. 70 (4–6): 257–262. doi:10.1016/S0960-0760(99)00115-6. ISSN 0960-0760.  https://dx.doi.org/10.1016%2FS0960-0760%2899%2900115-6
7. Jernström, H; Sandberg, T; Bågeman, E; Borg, Å; Olsson, H (2005). "Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families". Br. J. Cancer 92 (5): 857–866. doi:10.1038/sj.bjc.6602389. ISSN 0007-0920. PMID 15756256.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2361904
8. R.E. Mansel; Oystein Fodstad; Wen G. Jiang (14 June 2007). Metastasis of Breast Cancer. Springer Science & Business Media. pp. 217–. ISBN 978-1-4020-5866-0. https://books.google.com/books?id=14pb5b6gT-oC&pg=PA217. 
9. "Hormonal breast augmentation: prognostic relevance of insulin-like growth factor-I". Gynecol. Endocrinol. 12 (2): 123–7. 1998. doi:10.3109/09513599809024960. PMID 9610425.  https://dx.doi.org/10.3109%2F09513599809024960
10. Derek Leroith; Walter Zumkeller; Robert C. Baxter (31 July 2003). Insulin-like Growth Factor Receptor Signalling. Springer Science & Business Media. pp. 189–. ISBN 978-0-306-47846-8. https://books.google.com/books?id=2pJS5CeoUYIC&pg=PA189. 
11. Kleinberg, David L.; Ruan, Weifeng (2008). "IGF-I, GH, and Sex Steroid Effects in Normal Mammary Gland Development". J. Mammary Gland Biol. Neoplasia 13 (4): 353–360. doi:10.1007/s10911-008-9103-7. ISSN 1083-3021. PMID 19034633.  https://dx.doi.org/10.1007%2Fs10911-008-9103-7
12. Ismail Jatoi; Manfred Kaufmann (11 February 2010). Management of Breast Diseases. Springer Science & Business Media. pp. 19–. ISBN 978-3-540-69743-5. https://books.google.com/books?id=nsUBW3-qJ9MC&pg=PA19. 
13. Suzanne B. Cassidy; Judith E. Allanson (20 September 2011). Management of Genetic Syndromes. John Wiley & Sons. pp. 1330–. ISBN 978-1-118-21067-3. https://books.google.com/books?id=E8sHMf96uuoC&pg=PT1330. 
14. "The patient with Turner syndrome: puberty and medical management concerns". Fertil. Steril. 98 (4): 780–6. 2012. doi:10.1016/j.fertnstert.2012.07.1104. PMID 22884020.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3760009
15. "Endocrine consequences of anorexia nervosa". Lancet Diabetes Endocrinol. 2 (7): 581–92. 2014. doi:10.1016/S2213-8587(13)70180-3. PMID 24731664.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4133106
16. "Effects of recombinant human insulin-like growth factor (IGF)-I and estrogen administration on IGF-I, IGF binding protein (IGFBP)-2, and IGFBP-3 in anorexia nervosa: a randomized-controlled study". J. Clin. Endocrinol. Metab. 88 (3): 1142–9. 2003. doi:10.1210/jc.2002-021402. PMID 12629097.  https://dx.doi.org/10.1210%2Fjc.2002-021402
17. "Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa". J. Clin. Endocrinol. Metab. 87 (6): 2883–91. 2002. doi:10.1210/jcem.87.6.8574. PMID 12050268.  https://dx.doi.org/10.1210%2Fjcem.87.6.8574
18. James Barrett (2007). Transsexual and Other Disorders of Gender Identity: A Practical Guide to Management. Radcliffe Publishing. pp. 172–. ISBN 978-1-85775-719-4. https://books.google.com/books?id=I-8qZlGIpnQC&pg=PA172. 
19. "The potential clinical applications of insulin-like growth factor-1 ligand in human breast cancer". Anticancer Res. 27 (3B): 1617–24. 2007. PMID 17595785. http://ar.iiarjournals.org/cgi/pmidlookup?view=long&pmid=17595785. 
20. "Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions". Endocr. Rev. 30 (1): 51–74. 2009. doi:10.1210/er.2008-0022. PMID 19075184.  https://dx.doi.org/10.1210%2Fer.2008-0022
21. Alice C. Levine (3 October 2011). Hormones and Cancer: Breast and Prostate, An Issue of Endocrinology and Metabolism Clinics of North America,. Elsevier Health Sciences. pp. 26–. ISBN 1-4557-1239-6. https://books.google.com/books?id=ZabQAQAAQBAJ&pg=PT26. 
22. Douglas Yee (2004). Insulin-like Growth Factors. IOS Press. pp. 33–. ISBN 978-1-58603-409-2. https://books.google.com/books?id=y-tZ989CulEC&pg=PA33. 
23. "Growth hormone treatment induces mammary gland hyperplasia in aging primates". Nat. Med. 3 (10): 1141–4. 1997. doi:10.1038/nm1097-1141. PMID 9334728.  https://dx.doi.org/10.1038%2Fnm1097-1141
24. Sat Dharam Kaur (2003). The Complete Natural Medicine Guide to Breast Cancer: A Practical Manual for Understanding, Prevention & Care. R. Rose. p. 79. ISBN 978-0-7788-0083-5. https://books.google.com/books?id=_MAhAQAAMAAJ. 
25. Souza, Flavio Moutinho; Collett-Solberg, Paulo Ferrez (2011). "Adverse effects of growth hormone replacement therapy in children". Arq. Bras. Endocrinol. Metab. 55 (8): 559–565. doi:10.1590/S0004-27302011000800009. ISSN 0004-2730.  https://dx.doi.org/10.1590%2FS0004-27302011000800009
26. Zvi Laron; J. Kopchick (25 November 2010). Laron Syndrome - From Man to Mouse: Lessons from Clinical and Experimental Experience. Springer Science & Business Media. pp. 113, 498. ISBN 978-3-642-11183-9. https://books.google.com/books?id=THLPdLG4000C&pg=PA113. 
27. Laron, Zvi (2004). "Laron Syndrome (Primary Growth Hormone Resistance or Insensitivity): The Personal Experience 1958–2003". J. Clin. Endocrinol. Metab. 89 (3): 1031–1044. doi:10.1210/jc.2003-031033. ISSN 0021-972X. PMID 15001582.  https://dx.doi.org/10.1210%2Fjc.2003-031033
28. Brisken, Cathrin (2002). "Hormonal Control of Alveolar Development and Its Implications for Breast Carcinogenesis". J. Mammary Gland Biol. Neoplasia 7 (1): 39–48. doi:10.1023/A:1015718406329. ISSN 1083-3021.  https://dx.doi.org/10.1023%2FA%3A1015718406329
29. McNally, Sara; Martin, Finian (2011). "Molecular regulators of pubertal mammary gland development". Ann. Med. 43 (3): 212–234. doi:10.3109/07853890.2011.554425. ISSN 0785-3890.  https://dx.doi.org/10.3109%2F07853890.2011.554425
30. "A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse)". Proc. Natl. Acad. Sci. U.S.A. 94 (24): 13215–20. 1997. doi:10.1073/pnas.94.24.13215. PMID 9371826.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=24289
31. Walker, J. L.; Crock, P. A.; Behncken, S. N.; Rowlinson, S. W.; Nicholson, L. M.; Boulton, T. J. C.; Waters, M. J. (1998). "A Novel Mutation Affecting the Interdomain Link Region of the Growth Hormone Receptor in a Vietnamese Girl, and Response to Long-Term Treatment with Recombinant Human Insulin-Like Growth Factor-I and Luteinizing Hormone-Releasing Hormone Analogue1". J. Clin. Endocrinol. Metab. 83 (7): 2554–2561. doi:10.1210/jcem.83.7.4954. ISSN 0021-972X.  https://dx.doi.org/10.1210%2Fjcem.83.7.4954
32. Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". J. Clin. Endocrinol. Metab. 91 (3): 799–805. doi:10.1210/jc.2005-1536. ISSN 0021-972X. PMID 16352683.  https://dx.doi.org/10.1210%2Fjc.2005-1536
33. Copinschi, G; Van Onderbergen, A; L'Hermite-Balériaux, M; Mendel, C M; Caufriez, A; Leproult, R; Bolognese, J A; De Smet, M et al. (1996). "Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.". J. Clin. Endocrinol. Metab. 81 (8): 2776–2782. doi:10.1210/jcem.81.8.8768828. ISSN 0021-972X.  https://dx.doi.org/10.1210%2Fjcem.81.8.8768828
34. "The growth hormone secretagogue receptor". Vitam. Horm. 77: 47–88. 2008. doi:10.1016/S0083-6729(06)77004-2. PMID 17983853.  https://dx.doi.org/10.1016%2FS0083-6729%2806%2977004-2
35. "Novel mechanisms of growth hormone regulation: growth hormone-releasing peptides and ghrelin". Braz. J. Med. Biol. Res. 39 (8): 1003–11. 2006. doi:10.1590/s0100-879x2006000800002. PMID 16906274.  https://dx.doi.org/10.1590%2Fs0100-879x2006000800002
36. "Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system". Endocrine 14 (1): 35–43. 2001. doi:10.1385/endo:14:1:035. PMID 11322500.  https://dx.doi.org/10.1385%2Fendo%3A14%3A1%3A035
37. Marie Dunford; J. Doyle (3 February 2014). Nutrition for Sport and Exercise. Cengage Learning. pp. 190–. ISBN 978-1-285-75249-5. https://books.google.com/books?id=xRAeCgAAQBAJ&pg=PA190. 
38. Ira Wolinsky; Judy A. Driskell (25 June 2004). Nutritional Ergogenic Aids. CRC Press. pp. 27–28. ISBN 978-0-203-50770-4. https://books.google.com/books?id=Ix8l0yAHqvUC&pg=PA27. 
39. Fred Brouns; Cerestar-Cargill (7 February 2003). Essentials of Sports Nutrition. John Wiley & Sons. pp. 141–. ISBN 978-0-470-85536-2. https://books.google.com/books?id=QolubvuTbowC&pg=PA141. 
40. Joseph F. Audette; Allison Bailey (26 February 2008). Integrative Pain Medicine: The Science and Practice of Complementary and Alternative Medicine in Pain Management. Springer Science & Business Media. pp. 159–. ISBN 978-1-59745-344-8. https://books.google.com/books?id=GWQr7FJhBe0C&pg=PA159. 
41. "Acute creatine loading enhances human growth hormone secretion". J. Sports Med. Phys. Fit. 40 (4): 336–42. 2000. PMID 11297004.  http://www.ncbi.nlm.nih.gov/pubmed/11297004
42. Template:Vcite2 journal
43. Template:Vcite2 journal
44. Template:Vcite2 journal
45. Wanda M. Haschek; Colin G. Rousseaux; Matthew A. Wallig (1 May 2013). Haschek and Rousseaux's Handbook of Toxicologic Pathology. Elsevier Science. pp. 2675–. ISBN 978-0-12-415765-1. https://books.google.com/books?id=RXsdAAAAQBAJ&pg=PA2675. 
46. "Vitamin D and the mammary gland: a review on its role in normal development and breast cancer". Breast Cancer Res. 14 (3): 211. 2012. doi:10.1186/bcr3178. PMID 22676419.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3446331
47. "Targets of vitamin D receptor signaling in the mammary gland". J. Bone Miner. Res. 22 Suppl 2: V86–90. 2007. doi:10.1359/jbmr.07s204. PMID 18290729.  https://dx.doi.org/10.1359%2Fjbmr.07s204
48. "Vitamin D metabolism in mammary gland and breast cancer". Mol. Cell. Endocrinol. 347 (1–2): 55–60. 2011. doi:10.1016/j.mce.2011.05.020. PMID 21669251.  https://dx.doi.org/10.1016%2Fj.mce.2011.05.020
49. Pauline M. Camacho (26 September 2012). Evidence-Based Endocrinology. Lippincott Williams & Wilkins. pp. 20–. ISBN 978-1-4511-7146-4. https://books.google.com/books?id=s06wXkPAnfcC&pg=PA20. 
50. Isotton, A. L.; Wender, M. C. O.; Casagrande, A.; Rollin, G.; Czepielewski, M. A. (2011). "Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study". Eur. J. Endocrinol. 166 (2): 207–213. doi:10.1530/EJE-11-0560. ISSN 0804-4643. PMID 22108915. http://www.eje-online.org/content/166/2/207.full.pdf. 
51. Sonnet, Emmanuel; Lacut, Karine; Roudaut, Nathalie; Mottier, Dominique; Kerlan, Véronique; Oger, Emmanuel (2007). "Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study". Clin. Endocrinol. 66 (5): 626–631. doi:10.1111/j.1365-2265.2007.02783.x. ISSN 0300-0664. PMID 17492948.  https://dx.doi.org/10.1111%2Fj.1365-2265.2007.02783.x
52. "Breast size in relation to endogenous hormone levels, body constitution, and oral contraceptive use in healthy nulligravid women aged 19-25 years". Am. J. Epidemiol. 145 (7): 571–80. 1997. doi:10.1093/oxfordjournals.aje.a009153. PMID 9098173. http://aje.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=9098173. 
53. "Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression". FASEB J. 14 (12): 1725–30. 2000. doi:10.1096/fj.99-0863com. PMID 10973921. http://www.fasebj.org/cgi/pmidlookup?view=long&pmid=10973921. 
54. "Physical and hormonal evaluation of transsexual patients: a longitudinal study". Arch. Sex. Behav. 15 (2): 121–38. 1986. doi:10.1007/bf01542220. PMID 3013122.  https://dx.doi.org/10.1007%2Fbf01542220
55. Lawrence F. Ditmier (1 January 2006). New Developments in Obesity Research. Nova Publishers. pp. 20–21. ISBN 978-1-60021-296-3. https://books.google.com/books?id=BfeTsTAiq6MC&pg=PA20. 
56. Peter G. Kopelman; Ian D. Caterson; William H. Dietz (15 April 2008). Clinical Obesity in Adults and Children. John Wiley & Sons. pp. 202–. ISBN 978-1-4051-4366-0. https://books.google.com/books?id=qGVnItPoPCYC&pg=PA202. 
57. Robert H. Eckel (2003). Obesity: Mechanisms and Clinical Management. Lippincott Williams & Wilkins. pp. 157–. ISBN 978-0-7817-2844-7. https://books.google.com/books?id=v_NXqwsljYYC&pg=PA157. 
58. "Milk consumption and circulating insulin-like growth factor-I level: a systematic literature review". Int. J. Food Sci. Nutr. 60 Suppl 7: 330–40. 2009. doi:10.1080/09637480903150114. PMID 19746296.  https://dx.doi.org/10.1080%2F09637480903150114
59. Jerome F. Strauss, III; Robert L. Barbieri (13 September 2013). Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. pp. 236–. ISBN 978-1-4557-2758-2. https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA236. 
60. Christopher B. Wilson; Victor Nizet; Yvonne Maldonado; Jack S. Remington; Jerome O. Klein (24 February 2015). Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant. Elsevier Health Sciences. pp. 190–. ISBN 978-0-323-24147-2. https://books.google.com/books?id=VuZ1BwAAQBAJ&pg=PA190. 
61. Jeanne Held-Warmkessel (2006). Contemporary Issues in Prostate Cancer: A Nursing Perspective. Jones & Bartlett Learning. pp. 256–. ISBN 978-0-7637-3075-8. https://books.google.com/books?id=dZe4ZSVDdBsC&pg=PA256. 
62. "Drug-induced gynecomastia". Pharmacotherapy 32 (12): 1123–40. 2012. doi:10.1002/phar.1138. PMID 23165798.  https://dx.doi.org/10.1002%2Fphar.1138
63. "Gynaecomastia--pathophysiology, diagnosis and treatment". Nat. Rev. Endocrinol. 10 (11): 684–98. 2014. doi:10.1038/nrendo.2014.139. PMID 25112235.  https://dx.doi.org/10.1038%2Fnrendo.2014.139
64. Jeffrey K. Aronson (2 March 2009). Meyler's Side Effects of Cardiovascular Drugs. Elsevier. pp. 255–. ISBN 978-0-08-093289-7. https://books.google.com/books?id=oeBgU3UwgZkC&pg=PA255. 
65. Kenneth L. Becker (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1196–. ISBN 978-0-7817-1750-2. https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196. 
66. Sarah H. Wakelin; Howard I. Maibach; Clive B. Archer (21 May 2015). Handbook of Systemic Drug Treatment in Dermatology, Second Edition. CRC Press. pp. 29–. ISBN 978-1-4822-2286-9. https://books.google.com/books?id=fCysCQAAQBAJ&pg=PA29. 
67. "The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia". Cancer Res. 65 (11): 4496–9. 2005. doi:10.1158/0008-5472.CAN-05-0129. PMID 15930264.  https://dx.doi.org/10.1158%2F0008-5472.CAN-05-0129
68. "Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme". Cell. Signal. 19 (9): 1956–63. 2007. doi:10.1016/j.cellsig.2007.05.003. PMID 17572069.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2681182
69. "Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis". Breast Cancer Res. Treat. 149 (2): 525–36. 2015. doi:10.1007/s10549-015-3267-9. PMID 25589172.  https://dx.doi.org/10.1007%2Fs10549-015-3267-9
70. Zhong, Aimei; Wang, Guohua; Yang, Jie; Xu, Qijun; Yuan, Quan; Yang, Yanqing; Xia, Yun; Guo, Ke et al. (2014). "Stromal-epithelial cell interactions and alteration of branching morphogenesis in macromastic mammary glands". J Cell Mol Med 18 (7): 1257–1266. doi:10.1111/jcmm.12275. ISSN 1582-1838. PMID 24720804.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4124011
71. Benoist, C. C.; Kawas, L. H.; Zhu, M.; Tyson, K. A.; Stillmaker, L.; Appleyard, S. M.; Wright, J. W.; Wayman, G. A. et al. (2014). "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System". J. Pharmacol. Exp. Ther. 351 (2): 390–402. doi:10.1124/jpet.114.218735. ISSN 1521-0103. PMID 25187433.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4201273
72. "Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade". Cancer Res. 70 (11): 4453–9. 2010. doi:10.1158/0008-5472.CAN-09-4502. PMID 20460509.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2907250
73. Talghini, Shahla (2013). "Is Macromastia a Risk Factor for Breast Cancer? A Study on 198 Patients". Pak. J. Biol. Sci. 16 (21): 1348–1352. doi:10.3923/pjbs.2013.1348.1352. PMID 24511745.  https://dx.doi.org/10.3923%2Fpjbs.2013.1348.1352
74. Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Science. 1 August 2014. pp. 946–. ISBN 978-0-12-386457-4. https://books.google.com/books?id=uQB0AwAAQBAJ&pg=PA946. 
75. Jansen, L.A.; Backstein, R.M.; Brown, M.H. (2014). "Breast size and breast cancer: A systematic review". J. Plast. Reconstr. Aesthetic Surg. 67 (12): 1615–1623. doi:10.1016/j.bjps.2014.10.001. ISSN 1748-6815. PMID 25456291.  https://dx.doi.org/10.1016%2Fj.bjps.2014.10.001
76. Eriksson, Nicholas; Benton, Geoffrey M; Do, Chuong B; Kiefer, Amy K; Mountain, Joanna L; Hinds, David A; Francke, Uta; Tung, Joyce Y (2012). "Genetic variants associated with breast size also influence breast cancer risk". BMC Medical Genetics 13 (1): 53. doi:10.1186/1471-2350-13-53. ISSN 1471-2350. PMID 22747683.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3483246
77. "Oral contraceptives and breast cancer risk overall and by molecular subtype among young women". Cancer Epidemiol. Biomarkers Prev. 23 (5): 755–64. 2014. doi:10.1158/1055-9965.EPI-13-0944. PMID 24633144.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4032363
78. "Oral contraceptive use and breast cancer: a prospective study of young women". Cancer Epidemiol. Biomarkers Prev. 19 (10): 2496–502. 2010. doi:10.1158/1055-9965.EPI-10-0747. PMID 20802021.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3055790
79. Monica Morrow; Virgil Craig Jordan (2003). Managing Breast Cancer Risk. PMPH-USA. pp. 50–. ISBN 978-1-55009-260-8. https://books.google.com/books?id=HXKibhaF5lMC&pg=PA50. 
80. Lukanova, A.; Toniolo, P.; Zeleniuch-Jacquotte, A.; Grankvist, K.; Wulff, M.; Arslan, A. A.; Afanasyeva, Y.; Johansson, R. et al. (2006). "Insulin-like Growth Factor I in Pregnancy and Maternal Risk of Breast Cancer". Cancer Epidemiol. Biomarkers Prev. 15 (12): 2489–2493. doi:10.1158/1055-9965.EPI-06-0625. ISSN 1055-9965.  https://dx.doi.org/10.1158%2F1055-9965.EPI-06-0625
81. "Insulin-like growth factor-I and cancer risk". Growth Horm. IGF Res. 14 (4): 261–9. 2004. doi:10.1016/j.ghir.2004.01.005. PMID 15231294.  https://dx.doi.org/10.1016%2Fj.ghir.2004.01.005
82. "Breast cancer risk in BRCA1 mutation carriers: insight from mouse models". Ann. Oncol. 24 Suppl 8: viii8–viii12. 2013. doi:10.1093/annonc/mdt305. PMID 24131977.  https://dx.doi.org/10.1093%2Fannonc%2Fmdt305
83. "The insulin-like growth factor system and cancer". Cancer Lett. 195 (2): 127–37. 2003. doi:10.1016/s0304-3835(03)00159-9. PMID 12767520.  https://dx.doi.org/10.1016%2Fs0304-3835%2803%2900159-9
84. "Mechanisms by which IGF-I may promote cancer". Cancer Biol. Ther. 2 (6): 630–5. 2003. doi:10.4161/cbt.2.6.678. PMID 14688466.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4164051
85. "Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review". Cancer Epidemiol. Biomarkers Prev. 14 (1): 2–19. 2005. PMID 15668470.  http://www.ncbi.nlm.nih.gov/pubmed/15668470
86. "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on". Endocr. Relat. Cancer 13 (2): 273–8. 2006. doi:10.1677/erc.1.01219. PMID 16728563.  https://dx.doi.org/10.1677%2Ferc.1.01219
87. "Endogenous hormones and risk of breast cancer in postmenopausal women". Breast Dis. 24: 3–15. 2005. doi:10.3233/bd-2006-24102. PMID 16917136.  https://dx.doi.org/10.3233%2Fbd-2006-24102
88. "Circulating IGF-1 and its role in cancer: lessons from the IGF-1 gene deletion (LID) mouse". Novartis Found. Symp. 262: 3–9; discussion 9–18, 265–8. 2004. PMID 15562820.  http://www.ncbi.nlm.nih.gov/pubmed/15562820
89. "IGFs and human cancer: implications regarding the risk of growth hormone therapy". Horm. Res. 51 Suppl 3: 42–51. 1999. doi:10.1159/000053161. PMID 10592443.  https://dx.doi.org/10.1159%2F000053161
90. "Oncological complications of excess GH in acromegaly". Pituitary 5 (1): 21–5. 2002. PMID 12638722.  http://www.ncbi.nlm.nih.gov/pubmed/12638722
91. "Acromegaly: re-thinking the cancer risk". Rev. Endocr. Metab. Disord. 9 (1): 41–58. 2008. doi:10.1007/s11154-007-9063-z. PMID 18157698.  https://dx.doi.org/10.1007%2Fs11154-007-9063-z
92. "Acromegaly and cancer". Horm. Res. 62 Suppl 1: 108–15. 2004. doi:10.1159/000080768. PMID 15761242.  https://dx.doi.org/10.1159%2F000080768
93. Nathan A. Berger (19 June 2015). Murine Models, Energy Balance, and Cancer. Springer. pp. 76–. ISBN 978-3-319-16733-6. https://books.google.com/books?id=qdzyCQAAQBAJ&pg=PA76. 
94. Gallagher, Emily Jane; LeRoith, Derek (2011). "Is Growth Hormone Resistance/IGF-1 Reduction Good for You?". Cell Metab. 13 (4): 355–356. doi:10.1016/j.cmet.2011.03.003. ISSN 1550-4131. PMID 21459318.  https://dx.doi.org/10.1016%2Fj.cmet.2011.03.003
95. "Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?". Pharmacol. Res. 55 (5): 359–69. 2007. doi:10.1016/j.phrs.2007.01.020. PMID 17349798.  https://dx.doi.org/10.1016%2Fj.phrs.2007.01.020